Associated Papers
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Wilding B et al.
Cancer Discovery, 2025
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib.
Yang LL et al.
Translational Cancer Research, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Wilding B et al.
Nature Cancer, 2022
A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer.
Son J et al.
Cancer Research, 2022
Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study.
Koga T et al.
Translational Lung Cancer Research, 2021
Antitumour immunity regulated by aberrant ERBB family signalling.
Kumagai S et al.
Nature Reviews. Cancer, 2021
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini L et al.
Pharmacogenomics and Personalized Medicine, 2021
Molecular Pathology of Primary Non-small Cell Lung Cancer.
Suster DI et al.
Archives of Medical Research, 2020
Early-onset colorectal cancer: A distinct entity with unique genetic features.
Jiang D et al.
Oncology Letters, 2020
The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis.
Zhou N et al.
Translational Cancer Research, 2020
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
Baraibar I et al.
Critical Reviews in Oncology/hematology, 2020
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Koga T et al.
Lung Cancer (amsterdam, Netherlands), 2018
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.
Nagano M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Kosaka T et al.
Cancer Research, 2017
Activating HER2 mutations as emerging targets in multiple solid cancers.
Connell CM et al.
Esmo Open, 2017